Zuranolone
| Clinical data | |
|---|---|
| Pronunciation | /zʊˈrænəloʊn/ zuu-RAN-ə-lohn |
| Trade names | Zurzuvae |
| Other names | SAGE-217; S-812217; SGE-797; BIIB-125 |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a623048 |
| License data |
|
| Pregnancy category |
|
| Routes of administration | By mouth |
| Drug class | Neurosteroid; GABAA receptor positive allosteric modulator |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Protein binding | 99.5% |
| Metabolism | CYP3A4 |
| Elimination half-life | 16–23 hours |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.271.331 |
| Chemical and physical data | |
| Formula | C25H35N3O2 |
| Molar mass | 409.574 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Zuranolone, sold under the brand name Zurzuvae, is a medication used for the treatment of postpartum depression. It is taken by mouth. Zuranolone is a neuroactive steroid which enhances the activity of the neurotransmitter gamma-aminobutyric acid (GABA) and is thought to exert antidepressant effects by enhancing GABAergic inhibition.
The most common side effects include drowsiness, dizziness, diarrhea, fatigue, nasopharyngitis, and urinary tract infection.
Zuranolone was approved for medical use in the United States for the treatment of postpartum depression in August 2023. It was developed by Sage Therapeutics and Biogen.